{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:07:42Z","timestamp":1761523662737},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T00:00:00Z","timestamp":1341360000000},"content-version":"vor","delay-in-days":12087,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1979,6]]},"abstract":"<jats:p>1. Plasma levels of 5\u2010fluorouracil (5FU) have been determined in eleven cancer patients after 0.5 g and 1.0 g intravenous doses, and in one patient after paired 1.0 g oral and intravenous doses. 2. The plasma half\u2010life after the 0.5 g intravenous dose was relatively constant, irrespective of the stage and spread of the disease. 3. Plasma kinetics of the drug were dose dependent. Doubling of the intravenous dose produced a 1.5\u2010fold increase in plasma half life, a two\u2010fold increase in initial plasma drug concentration, and a three\u2010fold increase in area under the concentration\/time curve. 4. In one patient receiving paired 1.0 g intravenous and oral doses nine weeks apart, an increase in the bioavailability of the drug coincided with a marked clinical regression in palpable intra\u2010abdominal metastases. 5. The significance of measuring plasma drug kinetics and their relationship to drug efficacy and toxicity are discussed.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1979.tb04651.x","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T05:47:53Z","timestamp":1341467273000},"page":"613-617","source":"Crossref","is-referenced-by-count":49,"title":["Plasma levels of 5\u2010fluorouracil after oral and intravenous administration in cancer patients."],"prefix":"10.1111","volume":"7","author":[{"given":"RE","family":"Finch","sequence":"first","affiliation":[]},{"given":"MR","family":"Bending","sequence":"additional","affiliation":[]},{"given":"AF","family":"Lant","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2012,7,4]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1964.03070200122030"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803030-00002"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197816010-00003"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197401)33:1<14::AID-CNCR2820330106>3.0.CO;2-3"},{"key":"e_1_2_1_6_1","first-page":"165","article-title":"Clinical pharmacology of anticancer drugs","volume":"4","author":"CHABNER B.A.","year":"1977","journal-title":"Seminars in Oncology"},{"key":"e_1_2_1_7_1","first-page":"1045","article-title":"The physiological disposition of 5 fluorouracil in mice bearing solid L1210 lymphocytic leukemia","volume":"32","author":"CHADWICK M.","year":"1972","journal-title":"Cancer Res."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803040-00006"},{"key":"e_1_2_1_9_1","first-page":"723","article-title":"Clinical pharmacology of oral and intravenous 5 fluorouracil","volume":"58","author":"COHEN J.L.","year":"1974","journal-title":"Cancer Chemother. Rep."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196903)23:3<589::AID-CNCR2820230310>3.0.CO;2-A"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600671051"},{"key":"e_1_2_1_12_1","first-page":"279","article-title":"Determination of 5 fluorouracil plasma levels in rats by isotope dilution\u2010mass fragmentography","volume":"59","author":"FINN C.","year":"1975","journal-title":"Cancer Chemother. Rep."},{"key":"e_1_2_1_13_1","first-page":"411","article-title":"Changes in absorptive and peptide hydrolase activities in rat small intestine after administration of 5 fluorouracil","volume":"54","author":"GARDNER M.L.G.","year":"1978","journal-title":"Clin. Sci. mol. Med."},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600661019"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1971.59"},{"key":"e_1_2_1_16_1","first-page":"1226","article-title":"Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy","volume":"23","author":"HEIDELBERGER C.","year":"1963","journal-title":"Cancer Res."},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-73-6-897"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197106)27:6<1302::AID-CNCR2820270604>3.0.CO;2-5"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197301252880408"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1974.tb00205.x"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197702060-00004"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197507)36:1<123::AID-CNCR2820360108>3.0.CO;2-C"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb01679.x"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197709222971203"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1979.tb04651.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1979.tb04651.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T15:18:21Z","timestamp":1699715901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1979.tb04651.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1979,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1979,6]]}},"alternative-id":["10.1111\/j.1365-2125.1979.tb04651.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1979.tb04651.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1979,6]]}}}